Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Drug

Junshi Biosciences’ Toripalimab Gains TGA Approval for Nasopharyngeal Carcinoma

Fineline Cube Jan 20, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval...

Company

Inscinstech Secures C-Series Financing for Biopharma Expansion

Fineline Cube Jan 19, 2025

Inscinstech Co., Ltd., a leading intelligent technology company based in Suzhou, has successfully completed a...

Company

Raytone Bio Completes Angel Round to Advance iSus® Platform

Fineline Cube Jan 18, 2025

Raytone Bio, a Shenzhen-based biopharmaceutical company, has announced the completion of a multi-million RMB Angel...

Company Drug

Aosaikang’s Limertinib Approved for EGFR T790M-Mutated NSCLC

Fineline Cube Jan 18, 2025

Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK Pharm, SHE: 002755) has recently received approval from the...

Company Drug

Johnson & Johnson Submits NDA for TAR-200 in High-Risk Bladder Cancer

Fineline Cube Jan 17, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced the initiation of the submission of...

Company Drug

Eli Lilly’s Omvoh Approved by FDA for Crohn’s Disease Treatment

Fineline Cube Jan 17, 2025

US major Eli Lilly and Company (NYSE: LLY) has announced receiving marketing approval from the...

Company Deals

IVIEW Therapeutics Secures Series A++ Funding for Ophthalmology Pipeline

Fineline Cube Jan 17, 2025

IVIEW Therapeutics Inc., an ophthalmology biotech operating out of the US and China, has reportedly...

Company Drug

Boehringer Ingelheim’s Iclepertin Fails to Meet Phase III Study Endpoints

Fineline Cube Jan 17, 2025

German giant Boehringer Ingelheim has disclosed negative top-line results from the Phase III CONNEX study...

Company Drug

Telix Pharmaceuticals’ TLX591-CDx Approved in Europe via Decentralized Procedure

Fineline Cube Jan 17, 2025

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that the marketing filing in Europe via...

Policy / Regulatory

NMPA Implements Regulatory Reforms for Drug and Medical Device Industries

Fineline Cube Jan 17, 2025

The National Medical Products Administration (NMPA) has released a notification regarding the implementation of the...

Company Deals Drug

Daiichi Sankyo Acquires Gatipotuzumab IP Rights for $132.5M

Fineline Cube Jan 17, 2025

Japan-based Daiichi Sankyo Company, Ltd (TYO: 4568) has announced an investment of USD 132.5 million...

Policy / Regulatory

NHSA Pushes for Real-Time Settlement Reform in Basic Medical Insurance

Fineline Cube Jan 17, 2025

The National Healthcare Security Administration (NHSA) has released a notification to promote the real-time settlement...

Company Deals

a16z Bio + Health Launches Biotech Ecosystem Venture Fund

Fineline Cube Jan 17, 2025

Andreessen Horowitz (a16z) Bio + Health has announced the establishment of the Biotech Ecosystem Venture...

Company Drug

Impact Therapeutics’ Senaparib Cleared by NMPA for Ovarian Cancer Therapy

Fineline Cube Jan 17, 2025

China-based Impact Therapeutics has announced receiving marketing clearance from the National Medical Products Administration (NMPA)...

Company

Siemens Lays Foundation for New Medical Equipment Base in Shenzhen

Fineline Cube Jan 17, 2025

Siemens (Shenzhen) Magnetic Resonance Co., Ltd., a wholly-owned subsidiary of Siemens Ltd., China, has officially...

Company Deals

Fujian Haixi Pharmaceuticals Files for Hong Kong IPO

Fineline Cube Jan 17, 2025

China-based Fujian Haixi Pharmaceuticals Co., Ltd., a commercial-stage innovative pharmaceutical company, has made an initial...

Company Drug

SciClone and Menarini Submit NDA for Vaborem in China

Fineline Cube Jan 17, 2025

China-based SciClone Pharmaceuticals Inc and its Italy-based strategic partner Menarini have announced the submission of...

Company Deals

Servier and Google Cloud Extend Partnership to Advance AI in Drug Development

Fineline Cube Jan 17, 2025

France-based Servier Group and US technology firm Google Cloud have announced an expansion to their...

Company Deals

Cathay Biotech Plans $901M Private Placement to Boost Bio-Based Materials

Fineline Cube Jan 17, 2025

Shanghai-based Cathay Biotech Inc. (SHA: 688065) has announced plans to raise RMB 6.6 billion (USD...

Company Deals

Simcere Licenses Fermion’s AI-Enabled Painkiller FZ002-037

Fineline Cube Jan 17, 2025

China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced a licensing agreement with compatriot firm...

Posts pagination

1 … 277 278 279 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.